Q3 2024 results show solid growth with revenue up 8.1% YoY, and operating profit up 20.3% YoY. Read why I remain bullish on ...

The stock market has seen some top-performing IPOs that provided outstanding returns and solid long-term performance.

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

There are about three weeks to go until Selection Sunday on March 16, and the Bubble Watch picture for the 2025 men's NCAA ...